Pharmaceutical giant Eli Lilly has announced it is instituting a $35 dollar monthly cap on out-of-pocket insulin expenses. The company announced on Wednesday that it is moving forward with โprice reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or